European Journal of Chemistry

Dopamine antagonists for the treatment of drug addiction: PF-4363467 and related compounds

Article Sidebar

PDF
Published: Mar 31, 2020
DOI: https://doi.org/10.5155/eurjchem.11.1.84-90.1970
Keywords:
Drug design, Biomolecule, Antipsychotics, Donor acceptor map, Computational chemistry, Density functional calculations
Section
Research Article
Issue
Vol. 11 No. 1 (2020): March 2020
Dates
Received 2020-02-12
Accepted 2020-02-28
Published 2020-03-31
Crossmark


Main Article Content

Ana Martinez
Departamento de Materiales de Baja Dimensionalidad, Instituto de Investigaciones en Materiales, Universidad Nacional Autonoma de Mexico, Circuito Exterior S/N, Ciudad Universitaria. Coyoacan, CP 04510, CDMX, Mexico
http://orcid.org/0000-0002-0515-1946

Abstract

Drug addiction refers to an out-of-control and compulsive use of substances, which can reach epidemic magnitudes. It is a health concern throughout the world and has major economic impact. Dopamine receptor agonists and antagonists have been cited as molecular targets for the treatment of drug addiction. In this report, the main idea is to analyze the new D3R/D2R ligands that are proposed for the treatment of drug abuse, in terms of their electron donor/acceptor properties. Substances catalogued as agonists represent good electron donors, whereas antagonists represent good electron acceptors. HOMO and LUMO eigenvalues indicate that more energy is necessary to remove an electron from the antagonists, and likewise more energy is gained when antagonists accept an electron. The combination of two molecules (PF-592379 and PNU-177864) produces a new compound (PF-4363467) with properties that are intermediate. Irrespective of the characteristics of the receptor, the classification of ligands is important, in order to further understanding of the reaction mechanism of these compounds. This may help in the design of new molecules for the treatment of drug addiction.


icon graph This Abstract was viewed 2464 times | icon graph Article PDF downloaded 738 times

How to Cite
(1)
Martinez, A. Dopamine Antagonists for the Treatment of Drug Addiction: PF-4363467 and Related Compounds. Eur. J. Chem. 2020, 11, 84-90.

Article Details

Share
Links for Article


Crossref - Scopus - Google - European PMC
Crossref
Scopus
Google Scholar
Europe PMC
References

[1]. National Institute on Drug Abuse, Drugs, Brains, and Behaviour: The Science of Addiction, NIH Publication: USA, 2014.

[2]. Singh, J.; Gupta, P. Inter. J. Indian Psych. 2017, 5, 2348-5396.

[3]. Medina-Mora, M. E.; Cravioto, P.; Ortiz, A.; Kuri, P.; Villatoro, J. Bull. Narcotics. 2003, 55, 105-119.

[4]. Wager, T. T.; Chandrasekaran, R. Y.; Bradley, J.; Rubitski, D.; Berke, H.; Mente, S.; Butler, T.; Doran, A.; Chang, C.; Fisher, K.; Knafels, J.; Liu, S.; Ohren, J.; Marconi, M.; DeMarco, G.; Sneed, B.; Walton, K.; Horton, D.; Rosado, A.; Mead, A. ACS Chem. Neurosci. 2014, 5, 1253-1265.
https://doi.org/10.1021/cn500201x

[5]. Sokoloff, P.; Giros, B.; Martres, M. P.; Bouthenet, M. L.; Schwartz, J. C. Nature 1990, 347, 146-151.
https://doi.org/10.1038/347146a0

[6]. Newman, A. H.; Grundt, P.; Nader, M. A. J. Med. Chem. 2005, 48, 3663-3679.
https://doi.org/10.1021/jm040190e

[7]. Heidbreder, C. A.; Newman, A. H. Ann. NY Acad. Sci. 2010, 1187, 4-34.
https://doi.org/10.1111/j.1749-6632.2009.05149.x

[8]. Cho, D.; Zheng, M.; Kim, K. M. Arch. Pharmacal. Res. 2010, 33, 1521-1538.
https://doi.org/10.1007/s12272-010-1005-8

[9]. Keck, T. M.; John, W. S.; Czoty, P. W.; Nader, M. A.; Newman, A. H. J. Med. Chem. 2015, 58, 5361-5380.
https://doi.org/10.1021/jm501512b

[10]. Micheli, F.; Arista, L.; Bonanomi, G.; Blaney, F. E.; Braggio, S.; Capelli, A. M.; Checchia, A.; Damiani, F.; Di-Fabio, R.; Fontana, S.; Gentile, G.; Griffante, C.; Hamprecht, D.; Marchioro, C.; Mugnaini, M.; Piner, J.; Ratti, E.; Tedesco, G.; Tarsi, L.; Terreni, S.; Worby, A.; Ashby Jr. , C. R.; Heidbreder, C. J. Med. Chem. 2010, 53, 374-391.
https://doi.org/10.1021/jm901319p

[11]. Mugnaini, M.; Iavarone, L.; Cavallini, P.; Griffante, C.; Oliosi, B.; Savoia, C.; Beaver, J.; Rabiner, E. A.; Micheli, F.; Heidbreder, C.; Andorn, A.; Pich, E. M.; Bani, M. Neuropsychopharmacology 2013, 38, 302-312.
https://doi.org/10.1038/npp.2012.171

[12]. Pilla, M.; Perachon, S.; Sautel, F.; Garridok, F.; Mannk, A.; Wermuthk, C. G.; Schwartz, J. C.; Everitt, B. J.; Sokoloff, P. Nature 1999, 400, 371-375.
https://doi.org/10.1038/22560

[13]. Le Foll, B.; Goldberg, S. R.; Sokoloff, P. Neuropharmacology 2005, 49, 525-541.
https://doi.org/10.1016/j.neuropharm.2005.04.022

[14]. Roman, V.; Gyertyan, I.; Saghy, K.; Kiss, B.; Szombathelyi, Z. Psychopharmacology 2013, 226, 285-293.
https://doi.org/10.1007/s00213-012-2906-7

[15]. Li, P.; Snyder, G. L.; Vanover, K. E. Curr. Top Med. Chem. 2016, 16, 3385-3403.
https://doi.org/10.2174/1568026616666160608084834

[16]. Wickelgren, I. Science 1998, 281, 1264-1265.
https://doi.org/10.1126/science.281.5381.1264

[17]. Chauhan, A.; Mittal, A.; Arora, P. K. J. Pharm. Sci. Res. 2013, 4, 184-204.

[18]. Martinez, A.; Ibarra, I. A.; Vargas, R. PlosONE 2019, 14, e0224691.
https://doi.org/10.1371/journal.pone.0224691

[19]. Martinez, A.; Vargas, R. J. Pharm. Pharmaceut. Res. 2018, 1, 1-8.

[20]. Kiss, B.; Horvath, A.; Zs, N.; Schmidt, E.; Laszlovszky, I.; Gy, B.; Fazekas, K.; Hornok, K.; Sz, O.; Gyertyan, I.; Agai-Csongor, E.; Gy, D.; Tihanyi, K.; Adham, N.; Zs, S. J. Pharmacol. Exp. Ther. 2010, 333, 328-340.
https://doi.org/10.1124/jpet.109.160432

[21]. Gyertyan, I.; Kiss, B.; Saghy, K.; Laszy, J.; Gy, S.; Szabados, T.; Gemesi, L. I.; Pasztor, G.; Zajer-Balazs, M.; Kapas, M.; Agai-Csongor, E.; Gy, D.; Tihanyi, K.; Zs, S. Neurochem. In. 2011, 59, 925-935.
https://doi.org/10.1016/j.neuint.2011.07.002

[22]. McCormack, P. L. Drugs 2015, 75, 2035-2043.
https://doi.org/10.1007/s40265-015-0494-7

[23]. Wager, T. T.; Chappie, T.; Horton, D.; Chandrasekaran, R. Y.; Samas, B.; Dunn-Sims, E. R.; Hsu, C.; Nawreen, N.; Vanase-Frawley, M. A.; O'Connor, R. E.; Schmidt, C. J.; Dlugolenski, K.; Stratman, N. C.; Majchrzak, M. J.; Kormos, B. L.; Nguyen, D. P.; Sawant-Basak, A.; Mead, A. N. ACS Chem. Neurosci. 2017, 8, 165-177.
https://doi.org/10.1021/acschemneuro.6b00297

[24]. Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Montgomery, Jr. , J. A.; Vreven, T.; Kudin, K. N.; Burant, J. C.; Millam, J. M.; Iyengar, S. S.; Tomasi, J.; Barone, V.; Mennucci, B.; Cossi, M.; Scalmani, G.; Rega, N.; Petersson, G. A.; Nakatsuji, H.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Klene, M.; Li, X.; Knox, J. E.; P. Hratchian, H.; Cross, J. B.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Ayala, P. Y.; Morokuma, K.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.; Zakrzewski, V. G.; Dapprich, S.; Daniels, A. D.; Strain, M. C.; Farkas, O.; Malick, D. K.; Rabuck, A. D.; Raghavachari, K.; Foresman, J. B.; Ortiz, J. V.; Cui, Q.; Baboul, A. G.; Clifford, S.; Cioslowski, J.; Stefanov, B. B.; Liu, G.; Liashenko, A.; Piskorz, P.; Komaromi, I.; Martin, R. L.; Fox, D. J.; Keith, T.; Al-Laham, M. A.; Peng, C. Y.; Nanayakkara, A.; Challacombe, M.; Gill, P. M. W.; Johnson, B.; Chen, W.; Wong, M. W.; Gonzalez, C.; Pople, J. A., Gaussian 09, revision A. 02, Gaussian, Inc. , Wallingford CT, 2009.

[25]. Zhao, Y.; Truhlar, D. G. Theor. Chem. Acc. 2008, 120, 215-241.
https://doi.org/10.1007/s00214-007-0310-x

[26]. Petersson, G. A.; Bennett, A.; Tensfeldt, T. G.; Al-Laham, M. A.; Shirley, W. A. J. Chem. Phys. 1988, 89, 2193-2218.
https://doi.org/10.1063/1.455064

[27]. Petersson, G. A.; Al-Laham, M. A. J. Chem. Phys. 1991, 94, 6081-6090.
https://doi.org/10.1063/1.460447

[28]. McLean, A. D.; Chandler, G. S. J. Chem. Phys. 1980, 72, 5639-5648.
https://doi.org/10.1063/1.438980

[29]. Raghavachari, K.; Binkley, J. S.; Seeger, R.; Pople, J. A. J. Chem. Phys. 1980, 72, 650-654.
https://doi.org/10.1063/1.438955

[30]. Marenich, A. V.; Cramer, C. J.; Truhlar, D. G. J. Phys. Chem. B. 2009, 113, 6378-6396.
https://doi.org/10.1021/jp810292n

[31]. Islam, N.; Ghosh, D. C. Eur. J. Chem. 2010, 1, 83-89.
https://doi.org/10.5155/eurjchem.1.2.83-89.26

[32]. Islam, N. Eur. J. Chem. 2011, 2, 448-454.
https://doi.org/10.5155/eurjchem.2.4.448-454.94

[33]. Gazquez, J. L.; Cedillo, A.; Vela. A. J. Phys. Chem. A. 2007, 111, 1966-1970.
https://doi.org/10.1021/jp065459f

[34]. Gazquez, J. L. J. Mex. Chem. Soc. 2008, 52, 3-10.

[35]. Martinez, A.; Rodriguez-Girones, M. A.; Barbosa, A.; Costas, M. J. Phys. Chem. A. 2008, 112, 9037-9042.
https://doi.org/10.1021/jp803218e

[36]. Martinez, A. J. Phys. Chem. B. 2009, 113. 4915-4921.
https://doi.org/10.1021/jp8102436

[37]. Ceron-Carrasco, J. P.; Bastida, A.; Requena, A.; Zuniga, J.; Miguel, B. J. Phys. Chem. B. 2010, 114, 4366-4372.
https://doi.org/10.1021/jp911846h

[38]. Pillegowda, M.; Periyasamy, G. Comput. Theor. Chem. 2018, 1129, 26-36.
https://doi.org/10.1016/j.comptc.2018.02.012

[39]. Alfaro, R. A. D.; Gomez-Sandoval, Z.; Mammino, L. J. Mol. Model. 2014, 20, 2337, 1-11.
https://doi.org/10.1007/s00894-014-2337-y

[40]. Duarte, C.; Lefebvre, C.; Chaperon, F.; Hamon, M.; Thiébot, M. H. Neuropsychopharmacology 2003, 28, 1903-1915.
https://doi.org/10.1038/sj.npp.1300276

[41]. Maramai, S.; Gemma, S.; Brogi, S.; Campiani, G.; Butini, S.; Stark, H.; Brindisi, M. Front. Neurosci. 2016, 10, 1-13, Article 451.
https://doi.org/10.3389/fnins.2016.00451

[42]. Garcia-Ladona, F. J.; Cox. B. F. CNS Drug Rev. 2003, 9, 141-158.
https://doi.org/10.1111/j.1527-3458.2003.tb00246.x

[43]. Wicke, K.; Garcia-Ladona, J. Eur. J. Pharmacol. 2001, 424, 85-90.
https://doi.org/10.1016/S0014-2999(01)01054-8

[44]. Xi, Z. X.; Gardner, E. L. CNS Drug Rev. 2007, 13, 240-259.
https://doi.org/10.1111/j.1527-3458.2007.00013.x

Supporting Agencies

Universidad Nacional Autonoma de Mexico (CONACYT) Coyoacan, Mexico.
Most read articles by the same author(s)
TrendMD

Dimensions - Altmetric - scite_ - PlumX

Downloads and views

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...
License Terms

License Terms

by-nc

Copyright © 2024 by Authors. This work is published and licensed by Atlanta Publishing House LLC, Atlanta, GA, USA. The full terms of this license are available at https://www.eurjchem.com/index.php/eurjchem/terms and incorporate the Creative Commons Attribution-Non Commercial (CC BY NC) (International, v4.0) License (http://creativecommons.org/licenses/by-nc/4.0). By accessing the work, you hereby accept the Terms. This is an open access article distributed under the terms and conditions of the CC BY NC License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited without any further permission from Atlanta Publishing House LLC (European Journal of Chemistry). No use, distribution, or reproduction is permitted which does not comply with these terms. Permissions for commercial use of this work beyond the scope of the License (https://www.eurjchem.com/index.php/eurjchem/terms) are administered by Atlanta Publishing House LLC (European Journal of Chemistry).